Guasparri I, Keller SA, Cesarman E (2004) KSHV vFLIP is essential for the survival of
infected lymphoma cells. J Exp Med 199(7):993–1003
Israel A (2010) The IKK complex, a central regulator of NF-kappaB activation. Cold Spring
Harb Perspect Biol 2(3):a000158
Field N et al (2003) KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 116(Pt
18):3721–3728
Brown HJ et al (2003) NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol
77(15):8532–8540
Guasparri I, Wu H, Cesarman E (2006) The KSHV oncoprotein vFLIP contains a TRAF-
interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep 7(1):114–119
McCormick C, Ganem D (2005) The kaposin B protein of KSHV activates the p38/MK2
pathway and stabilizes cytokine mRNAs. Science 307(5710):739–741
O’Hara AJ et al (2009) Pre-micro RNA signatures delineate stages of endothelial cell trans-
formation in Kaposi sarcoma. PLoS Pathog 5(4):e1000389
O’Hara AJ et al (2009) Tumor suppressor microRNAs are underrepresented in primary effu-
sion lymphoma and Kaposi sarcoma. Blood 113(23):5938–5941
Liang D, Lin X, Lan K (2011) Looking at Kaposi’s sarcoma-associated herpesvirus-host
interactions from a microRNA viewpoint. Front Microbiol 2:271
Lin X et al (2012) MicroRNAs and unusual small RNAs discovered in Kaposi’s sarcoma-
associated herpesvirus virions. J Virol 86(23):12717–12730
Liu Y et al (2012) Kaposi’s sarcoma-associated herpesvirus-encoded microRNA miR-K12- 11
attenuates transforming growth factor beta signaling through suppression of SMAD5. J Virol
86(3):1372–1381
Lin X et al (2011) miR-K12-7-5p encoded by Kaposi’s sarcoma-associated herpesvirus sta-
bilizes the latent state by targeting viral ORF50/RTA. PLoS One 6(1):e16224
Suffert G et al (2011) Kaposi’s sarcoma herpesvirus microRNAs target caspase 3 and regulate
apoptosis. PLoS Pathog 7(12):e1002405
Hansen A et al (2010) KSHV-encoded miRNAs target MAF to induce endothelial cell repro-
gramming. Genes Dev 24(2):195–205
Qin Z et al (2012) KSHV-encoded MicroRNAs: lessons for viral cancer pathogenesis and
emerging concepts. Int J Cell Biol 2012:603961
Liang D et al (2011) A human herpesvirus miRNA attenuates interferon signaling and con-
tributes to maintenance of viral latency by targeting IKKepsilon. Cell Res 21(5):793–806
Krishnan HH et al (2004) Concurrent expression of latent and a limited number of lytic genes
with immune modulation and antiapoptotic function by Kaposi’s sarcoma-associated herpes-
virus early during infection of primary endothelial and fibroblast cells and subsequent decline
of lytic gene expression. J Virol 78(7):3601–3620
Renne R et al (1996) Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human her-
pesvirus 8) in culture. Nat Med 2(3):342–346
Jenner RG et al (2001) Kaposi’s sarcoma-associated herpesvirus latent and lytic gene expres-
sion as revealed by DNA arrays. J Virol 75(2):891–902
Wang SE et al (2003) CCAAT/enhancer-binding protein-alpha is induced during the early
stages of Kaposi’s sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and
together with the KSHV replication and transcription activator (RTA) cooperatively stimu-
lates the viral RTA, MTA, and PAN promoters. J Virol 77(17):9590–9612
Deng H, Young A, Sun R (2000) Auto-activation of the rta gene of human herpesvirus-8/
Kaposi’s sarcoma-associated herpesvirus. J Gen Virol 81(Pt 12):3043–3048
Song MJ, Deng H, Sun R (2003) Comparative study of regulation of RTA-responsive genes
in Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. J Virol 77(17):9451–9462
Wang Y et al (2006) Kaposi’s sarcoma-associated herpesvirus ori-Lyt-dependent DNA repli-
cation: dual role of replication and transcription activator. J Virol 80(24):12171–12186
Chen J et al (2009) Genome-wide identification of binding sites for Kaposi’s sarcoma-
associated herpesvirus lytic switch protein. RTA Virology 386(2):290–302
